FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT C	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* STEPHENSON BRIAN C				2. Issuer Name and Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO]									ationship of Reporti k all applicable) Director Officer (give title below)		10% O		wner (specify			
(Last) (First) (Middle) C/O BRIDGEBIO PHARMA, INC.						3. Date of Earliest Transaction (Month/Day/Year) 02/03/2023									Secretary, Treasurer & C					
3160 PORTER DR., SUITE 250					4. If /	Amendi	ment. [Date	of Orio	ginal Fil	led (Month/D	av/Year) 6	6. Individual or Joint/Group Filing (Check Applicable						
(Street) PALO ALTO CA 94304						4. If Amendment, Date of Original Filed (Month/Day/Year)								X Form filed by One Reporting Person Form filed by More than One Reporting					on	
(City)	(St	ate) (Z	Zip)												Perso					
		Table	I - N	Non-Deriva	tive	Secur	rities	Ac	quire	ed, Di	sposed o	f, or E	Benefic	ially	Owne	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			Execution Date,		, 1	Transaction Disposed Of (I Code (Instr.		Acquired (A) or (D) (Instr. 3, 4 and		nd 5) Secui Bene		rities I eficially (ed Following I		wnership n: Direct or ect (I) r. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
								(Code	v .	Amount	(A) or (D)	Price	Trans		saction(s) r. 3 and 4)			(111301. 4)	
Common	Stock			02/03/202	23			S ⁽¹⁾		61,040	D	\$11.00	0079(2)		219,184		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year) (Month/Day/Year) 8)		Transa Code (Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4) Amou or Numb of Title Share:		nt er		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022.
- 2. Represents the weighted average sale price of the shares sold from \$10.61 to \$11.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote

Remarks:

/s/ Brian C. Stephenson 02/06/2023

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.